Tetradesmus obliquus Extract: A First Human Trial, Not Proof

Tetradesmus obliquus extract has its first human randomized trial. That is a reason to pay attention, not a reason to buy it. In a four-week study of 56 healthy adults with mild-to-moderate gastrointestinal distress, 250 mg per day of a proprietary extract improved the global gastrointestinal symptom score versus placebo (p=0.02). Yet the microbiome result failed correction for multiple testing, stool butyrate fell rather than rose, and the paper did not report effect sizes or 95% confidence intervals for symptom outcomes.

Those details change the interpretation. This study opens a plausible research program for a freshwater microalgae extract. It does not establish that the extract acts as a prebiotic, improves anxiety, or produces a clinically meaningful improvement in gut health.

A well-designed first look at an untested extract

Maltz et al.'s 2025 pilot trial appears to be the first human clinical study of T. obliquus, also associated with the older name Scenedesmus obliquus. The researchers randomly assigned 56 healthy adults to 250 mg/day of extract from proprietary strain Mi175.B1.a (TOME) or a matched placebo for four weeks. The trial used a double-blind, parallel-arm design and was preregistered as NCT06425094.

Those design choices matter. Randomization and blinding reduce the chance that expectations, treatment assignment, or researcher behavior explain a difference in subjective symptoms. Preregistration also makes it harder to select a favorable outcome after seeing the results. But careful design does not turn a small pilot into a conclusive efficacy trial; it makes the pilot worth taking seriously enough to test again.

The investigators measured gastrointestinal symptoms with the validated Gastrointestinal Symptom Rating Scale (GSRS), along with stool microbiome composition by 16S rRNA sequencing, stool short-chain fatty acids, and plasma chromogranin A (CgA) as a stress-related biomarker.

The symptom result is encouraging but incomplete

The TOME group improved on the GSRS global score, with p=0.02. The constipation and indigestion subscales also reached nominal significance, at p=0.05 and p=0.03, respectively. These findings justify a larger trial. They do not tell us how much better participants felt.

The publication did not report Cohen's d or 95% confidence intervals for these symptom outcomes. A p-value addresses compatibility with a null result under the study model; it does not show the size, precision, or clinical importance of an effect. With only 56 participants and no reported effect estimate, the global symptom finding could reflect a useful change, a modest change, or a result that does not replicate.

The subscale findings need even more restraint. Constipation at p=0.05 and indigestion at p=0.03 sit near the conventional threshold, and the study assessed several GSRS subscales. The global score had the clearest statistical signal, but it still needs replication with complete effect-size reporting.

The proposed prebiotic story runs into butyrate

The most awkward result for the extract's proposed mechanism is also the most informative: stool butyrate decreased in the TOME arm. If the extract improved symptoms by acting as a fermentable prebiotic substrate, a rise in short-chain fatty acid production, including butyrate, would fit that explanation better. The observed direction does not.

This does not prove that TOME has no biological activity. Stool metabolites do not capture every process in the colon, and a single four-week dose cannot map an ingredient's full physiology. Still, the trial cannot claim support for a butyrate-mediated prebiotic mechanism at 250 mg/day over four weeks.

That contrast matters because fermentable-fiber research provides a useful benchmark. In a randomized placebo-controlled trial in people with overweight, van Kalkeren et al. reported higher short-chain fatty acid production with a slowly fermentable fiber mixture. A 2025 systematic review and meta-analysis of prebiotic, probiotic, and synbiotic trials also places microbiome-targeted interventions in a much broader body of clinical evidence than this single pilot can provide. The populations, products, and endpoints differ, so these studies do not test TOME. They show what a more developed evidence base looks like.

The microbiome signal did not survive its own correction

Shannon diversity increased in the TOME group at a raw p=0.05. After false-discovery-rate correction, the p-value was 0.12. The corrected analysis is the result to use because microbiome studies test many related measures and therefore face a high false-positive risk.

In practical terms, the study did not demonstrate a statistically reliable microbiome-diversity change after accounting for multiple comparisons. Calling the raw result evidence that TOME reshapes the gut microbiome would overstate it.

Human trials of other phytochemical-rich interventions offer biological context but not a shortcut to an efficacy claim for this algae strain. A systematic review and meta-analysis of polyphenol-rich interventions found that these interventions can affect microbiota and inflammatory or oxidative-stress markers in adults with overweight or obesity. TOME contains a different mix of compounds, was studied in healthy adults, and produced a different pattern of microbiome and stool-metabolite results.

Plausibility is not human proof

There is a reasonable case for testing microalgal compounds in humans. A 2025 rat study found carotenoids and chlorophylls from microalgae in the cecum, showing that pigments in this class can reach gut tissue in an animal model. An in vitro digestion and colonic-fermentation study found that microalgal phenolics can remain bioaccessible and interact with colonic microbiota.

Neither finding predicts a health benefit in people taking this extract. Animal distribution studies establish neither human dose nor efficacy, and simulated fermentation is not a clinical trial. A systematic review of medicinal plants and the gut microbiome in mental health likewise supports the broader gut-brain hypothesis without validating T. obliquus itself.

The anxiety claim is weaker than the symptom claim

The trial measured plasma CgA as a stress index but reported no statistically significant between-group difference. That is a null result for the biomarker, not evidence that the extract reduced anxiety.

CgA also has a validation problem in this setting. A 2026 cross-sectional study of healthcare professionals linked salivary CgA with anxiety and depressive symptoms. It did not test plasma CgA, nutritional supplementation, healthy volunteers, or change over time. The association provides a rationale for research, not proof that plasma CgA is an intervention-sensitive anxiety endpoint in this trial.

What would make the evidence actionable?

The next study should be larger, independently run, and long enough to assess whether symptom changes persist. It should prespecify primary outcomes, report effect sizes and 95% confidence intervals for every GSRS result, and apply multiplicity correction to microbiome analyses. Testing more than one dose would help determine whether the butyrate decrease is reproducible or dose-related.

An active comparator such as a well-characterized prebiotic would also put any symptom change in context. Most importantly, a replication study must either find a neutral or favorable short-chain-fatty-acid pattern or offer evidence for a different mechanism that explains the decrease in butyrate.

Verdict: Wait. TOME has one transparent, reasonably designed pilot trial with a statistically significant global GI symptom result, but no reported symptom effect sizes, no FDR-surviving microbiome-diversity result, and a butyrate decrease that conflicts with its proposed prebiotic mechanism. The evidence supports further trials, not self-experimentation.